Jones, David R.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7

Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 471

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily

Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology

Pharmacogenetics and Drug MetabolismDrug-Induced Hepatotoxicity and Protection

Cited by 395

Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 49

Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity

Cai, S., Wang, H., Bailey, B., Ernstberger, A., Juliar, B. E., Sinn, A. L., Chan, R. J., Jones, D. R., Mayo, L. D., Baluyut, A. R., et al. (2011) · Clinical Cancer Research

Hematopoietic Stem Cell TransplantationImmunotoxicology and immune responses

Cited by 32

Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study

Onos, K. D., Quinney, S. K., Jones, D. R., Masters, A. R., Pandey, R., Keezer, K. J., Biesdorf, C., Metzger, I. F., Meyers, J. A., Peters, J., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 16